1. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. (1st August 2020) Authors: Simpson, E.L.; Lacour, J.‐P.; Spelman, L.; Galimberti, R.; Eichenfield, L.F.; Bissonnette, R.; King, B.A.; Thyssen, J.P.; Silverberg, J.I.; Bieber, T.; Kabashima, K.; Tsunemi, Y.; Costanzo, A.; Guttman‐Yassky, E.; Beck, L.A.; Janes, J.M.; DeLozier, A.M.; Gamalo, M.; Brinker, D.R.; Cardillo, T. Journal: British journal of dermatology Issue: Volume 183:Number 2(2020) Page Start: 242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. (5th March 2020) Authors: Simpson, E.L.; Lacour, J.‐P.; Spelman, L.; Galimberti, R.; Eichenfield, L.F.; Bissonnette, R.; King, B.A.; Thyssen, J.P.; Silverberg, J.I.; Bieber, T.; Kabashima, K.; Tsunemi, Y.; Costanzo, A.; Guttman‐Yassky, E.; Beck, L.A.; Janes, J.M.; DeLozier, A.M.; Gamalo, M.; Brinker, D.R.; Cardillo, T. Journal: British journal of dermatology Issue: Volume 183:Number 2(2020) Page Start: 242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0013 Converting patient-reported physical function outcomes scores to promis metric scores in phase 3 trials of baricitinib in rheumatoid arthritis. (12th June 2018) Authors: Bingham, C.O.; Gaich, C.; DeLozier, A.M.; Quebe, A.; Sun, L.; Otawa, S.; Pope, J. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 553 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial. (5th June 2021) Authors: Wollenberg, A.; Nakahara, T.; Maari, C.; Peris, K.; Lio, P.; Augustin, M.; Silverberg, J.I.; Rueda, M.J.; DeLozier, A.M.; Pierce, E.; Yang, F.E.; Sun, L.; Ball, S.; Tauber, M.; Paul, C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 7(2021) Page Start: 1543 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAT0349 Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Tumor Necrosis Factor Inhibitors. (9th June 2015) Authors: Smolen, J.S.; Kremer, J.; Gaich, C.; DeLozier, A.M.; Schlichting, D.; Xie, L.; Genovese, M.C. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 785 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. THU0106 Converting patient-reported outcome measures of fatigue and pain to promis scores: data from phase 3 baricitinib rheumatoid arthritis trials. (12th June 2018) Authors: Bingham, C.O.; Gaich, C.; DeLozier, A.M.; Quebe, A.; Sun, L.; Otawa, S.; Pope, J. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 274 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0609 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Background Methotrexate Therapy. (15th July 2016) Authors: Keystone, E.; Taylor, P.; Tanaka, Y.; Gaich, C.; DeLozier, A.M.; Dudek, A.; Velasco Zamora, J.; Covarrubias Cobos, J.; de Bono, S.; Arora, V.; Yang, L.; Linetzky, B.; Weinblatt, M.E. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 412 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. THU0617 Work Productivity and Daily Activity in Patients with Rheumatoid Arthritis in Four Phase III Randomized Clinical Trials of Baricitinib. (15th July 2016) Authors: Smolen, J.S.; DeLozier, A.M.; de Bono, S.; Yang, L.; Gaich, C. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0623 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying anti-Rheumatic Drugs. (15th July 2016) Authors: Schiff, M.; Takeuchi, T.; Gaich, C.; DeLozier, A.M.; Schlichting, D.; Kuo, W.-L.; Durez, P.; Carmack, T.; Won, J.-E.; Fleischmann, R. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗